Sheenu Chandwani, Ph.D.
Affiliations: | 2012 | Epidemiology | Rutgers University, New Brunswick, New Brunswick, NJ, United States |
Area:
Public Health, Epidemiology, Oncology, African American StudiesGoogle:
"Sheenu Chandwani"Cross-listing: PHTree
Parents
Sign in to add mentor| Kitaw Demissie | grad student | 2012 | Rutgers, New Brunswick | |
| (Factors contributing to disparities in early breast cancer treatment.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Velcheti V, Chandwani S, Chen X, et al. (2020) Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival. Clinical Lung Cancer |
| Velcheti V, Chandwani S, Chen X, et al. (2019) Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices. Immunotherapy |
| Meng W, Ou W, Chandwani S, et al. (2019) Temporal phenotyping by mining healthcare data to derive lines of therapy for cancer. Journal of Biomedical Informatics. 103335 |
| Velcheti V, Chandwani S, Chen X, et al. (2019) First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment. Immunotherapy |
| El Ferjani B, Chandwani S, Hirschmann M, et al. (2019) HSR19-085: A Real World Observational Assessment of the Impact of Immunotherapy on the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Journal of the National Comprehensive Cancer Network. 17: HSR19-085 |
| Velcheti V, Chandwani S, Chen X, et al. (2019) Abstract 3307: Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC) Cancer Research. 79: 3307-3307 |
| Altini M, Massa I, Balzi W, et al. (2019) Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy Annals of Oncology. 30: ii63-ii64 |
| Williams L, Shi Q, El Ferjani B, et al. (2019) MA19.03 Differences in Symptom Burden Between Responsive and Progressive Disease in Advanced Non-Small Cell Lung Cancer (aNSCLC) Journal of Thoracic Oncology. 14: S327 |
| Altini M, Massa I, Balzi W, et al. (2019) EP1.16-04 Real World Clinical Outcomes for Metastatic Non-Small Cell Lung Cancer (mNSCLC) at IRST Italy Journal of Thoracic Oncology. 14: S1065-S1066 |
| Shi Q, Williams L, El Ferjani B, et al. (2019) P1.16-31 Body Mass Index Relating to Patient-Reported Symptoms in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 14: S599 |